An independent Data Monitoring Committee found that Keytruda in combination with chemotherapy followed by Keytruda plus Lynparza did not produce an improved overall survival benefit vs. Keytruda in combination with chemotherapy followed by Keytruda plus a placebo in patients with metastatic squamous non-small cell lung cancer.
A study explores how supply and demand impact the value of medication.
Novartis anticipates Fabhalta to be available in the United States in December for the treatment of paroxysmal nocturnal hemoglobinuria.
Eli Lilly and Company's obesity drug Zepbound (tirzepatide) has a list price of $1,059.87, which is approximately 20% less than the 2.4 mg semaglutide injection indicated for weight loss.
Johnson & Johnson’s TAR-200 has a novel targeted releasing system that allows for a controlled release of gemcitabine in patients with Bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer.
Opdivo (nivolumab) plus cisplatin-based chemotherapy shows improved survival benefits in the first-line treatment of adults with unresectable or metastatic urothelial carcinoma.
Critical factors need to be addressed for pharma stakeholders to realize the full potential of generative artificial intelligence.
Jaypirca (pirtobrutinib) is indicated for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma who received at least two prior lines of treatment with a Bruton tyrosine kinase inhibitor and a BCL2 inhibitor.
Ongoing clinical trials are evaluating zotatifin (eFT226) plus Faslodex (fulvestrant) and Verzenio (abemaciclib) for the treatment of ER–positive, HER2-negative advanced or metastatic breast cancer.
In clinical trials, Keytruda plus Padcev lowered the risk of disease progression or death by 55% compared with chemotherapy in adult patients with locally advanced or metastatic urothelial carcinoma.
Sphingosine-1-phosphate receptor modulator is designed to improve leukemia-free survival by increasing graft-versus-leukemia response.
In clinical trials, roflumilast cream demonstrated rapid and sustained improvement in the signs and symptoms of atopic dermatitis in patients 6 years of age and older.
The companies will partner up to design and implement solutions that support each other's business efforts.
In clinical trials, KarXT (xanomeline-trospium) demonstrated a combination of strong tolerability and clinically meaningful symptom reduction in adult patients with schizophrenia.
CDC finds administration rates for influenza antiviral medication was lower than during pre–COVID-19 pandemic flu seasons.
Biden Administration invokes Defense Production Act to facilitate domestic manufacturing of essential medicines.
Studies explore how both the UK and EU are handling these ongoing supply chain challenges.
The approval of Ogsiveo represents an important therapeutic advance for patients with progressing desmoid tumors requiring systemic treatment.
Investigation notes a need for greater transparency in 340B program revenue and strengthened enforcement authority for the Health Resources and Services Administration.
The designation—which ranks the fastest-growing companies in North America—is powered by AeroSafe’s 477% growth rate.
AbbVie and Genmab will share commercial responsibilities in the United States and Japan for epcoritamab-bysp (Epkinly) for the treatment of adults with follicular lymphoma that is relapsed or refractory following treatment with two or more therapies.
Alladapt Immunotherapeutics said the FDA Fast Track designation highlights the importance of developing a treatment for multiple food allergens.
Study aims to find ways industry gets involved in the most influential clinical trials, and how transparent these trials are.
The CDMO’s GMP plant will dedicate 2,500 square feet to the storage of finished products.
IQVIA report explores why these shortages are increasing, and how they can be mitigated.
Medication focuses on the acute treatment of migraines.
Study emphasizes role in bridging research and development and commercial/marketing functions.
IATA numbers point to continuing recovery.
Purchase grows the company’s CRYOPDP domestic footprint while strengthening working relationship between both parties.
The FDA also approved a companion diagnostic test to detect the PIK3CA, AKT1, and PTEN alterations as part of the approval for AstraZeneca’s capivasertib (Truqap) plus fulvestrant (Faslodex) for HR-positive, HER2-negative locally advanced or metastatic breast cancer.
